Literature DB >> 10708414

Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion.

J Martín1, G Dunn, R Hull, V Patel, P D Minor.   

Abstract

A 20-year-old female hypogammaglobulinemic patient received monotypic Sabin 3 vaccine in 1962. The patient excreted type 3 poliovirus for a period of 637 days without developing any symptoms of poliomyelitis, after which excretion appeared to have ceased spontaneously. The evolution of Sabin 3 throughout the entire period of virus excretion was studied by characterization of seven sequential isolates from the patient. The isolates were analyzed in terms of their antigenic properties, virulence, sensitivity for growth at high temperatures, and differences in nucleotide sequence from the Sabin type 3 vaccine. The isolates followed a main lineage of evolution with a rate of nucleotide substitution that was very similar to that estimated for wild-type poliovirus during person-to-person transmission. There was a delay in the appearance of antigenic variants compared to sequential type 3 isolates from healthy vaccines, which could be one of the possible explanations for the long-term excretion of virus from the patient. The distribution of mutations in the isolates identified regions of the virus possibly involved in adaptation for growth in the human gut and virus persistence. None of the isolates showed a full reversion of the attenuated and temperature-sensitive phenotypes of Sabin 3. Information of this sort will help in the assessment of the risk of spread of virulent polioviruses from long-term excretors and in the design of therapies to stop long-term excretion. This will make an important contribution to the decision-making process on when to stop vaccination once wild poliovirus has been eradicated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708414      PMCID: PMC111798          DOI: 10.1128/jvi.74.7.3001-3010.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Generation of virus genetic lineages during an outbreak of poliomyelitis.

Authors:  L Kinnunen; T Pöyry; T Hovi
Journal:  J Gen Virol       Date:  1991-10       Impact factor: 3.891

2.  An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain.

Authors:  A J Macadam; G Ferguson; C Arnold; P D Minor
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

3.  Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants.

Authors:  M Gromeier; L Alexander; E Wimmer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

Review 4.  Modification of translational control elements as a new approach to design of attenuated picornavirus strains.

Authors:  V I Agol; E V Pilipenko; O R Slobodskaya
Journal:  J Biotechnol       Date:  1996-01-26       Impact factor: 3.307

Review 5.  The 5' noncoding region and virulence of poliovirus vaccine strains.

Authors:  A J Macadam; D M Stone; J W Almond; P D Minor
Journal:  Trends Microbiol       Date:  1994-11       Impact factor: 17.079

Review 6.  Genetics of poliovirus.

Authors:  E Wimmer; C U Hellen; X Cao
Journal:  Annu Rev Genet       Date:  1993       Impact factor: 16.830

7.  Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions.

Authors:  A G Mosser; J Y Sgro; R R Rueckert
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

8.  Comparison of surface properties of picornaviruses: strategies for hiding the receptor site from immune surveillance.

Authors:  M S Chapman; M G Rossmann
Journal:  Virology       Date:  1993-08       Impact factor: 3.616

9.  Poliovirus protein 2C contains two regions involved in RNA binding activity.

Authors:  P L Rodríguez; L Carrasco
Journal:  J Biol Chem       Date:  1995-04-28       Impact factor: 5.157

10.  Role for poliovirus protease 2A in cap independent translation.

Authors:  A J Macadam; G Ferguson; T Fleming; D M Stone; J W Almond; P D Minor
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

View more
  58 in total

1.  Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model.

Authors:  G V Gavrilin; E A Cherkasova; G Y Lipskaya; O M Kew; V I Agol
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993.

Authors:  Chen-Fu Yang; Tary Naguib; Su-Ju Yang; Eman Nasr; Jaume Jorba; Nahed Ahmed; Ray Campagnoli; Harrie van der Avoort; Hiroyuki Shimizu; Tetsuo Yoneyama; Tatsuo Miyamura; Mark Pallansch; Olen Kew
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

3.  Multiplex PCR method for identifying recombinant vaccine-related polioviruses.

Authors:  David R Kilpatrick; Karen Ching; Jane Iber; Ray Campagnoli; Christopher J Freeman; Nada Mishrik; Hong-Mei Liu; Mark A Pallansch; Olen M Kew
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

4.  Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future.

Authors:  Ekaterina A Korotkova; Renee Park; Elena A Cherkasova; Galina Y Lipskaya; Konstantin M Chumakov; Esfir V Feldman; Olen M Kew; Vadim I Agol
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

5.  Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001.

Authors:  Hiroyuki Shimizu; Bruce Thorley; Fem Julia Paladin; Kerri Anne Brussen; Vicki Stambos; Lilly Yuen; Andi Utama; Yoshio Tano; Minetaro Arita; Hiromu Yoshida; Tetsuo Yoneyama; Agnes Benegas; Sigrun Roesel; Mark Pallansch; Olen Kew; Tatsuo Miyamura
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

6.  Long-term excretion of vaccine-derived poliovirus by a healthy child.

Authors:  Javier Martín; Kofi Odoom; Gráinne Tuite; Glynis Dunn; Nicola Hopewell; Gill Cooper; Catherine Fitzharris; Karina Butler; William W Hall; Philip D Minor
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

7.  Application of a molecular panel to demonstrate enterotropic virus shedding by healthy and human immunodeficiency virus-infected patients.

Authors:  Claudia Minosse; Maria S Zaniratti; Silvia Calcaterra; Fabrizio Carletti; Michele Muscillo; Marina Pisciotta; Letizia Pillitteri; Angela Corpolongo; Francesco Nicola Lauria; Pasquale Narciso; Gianfranco Anzidei; Maria R Capobianchi
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

8.  Identification of vaccine-derived polioviruses using dual-stage real-time RT-PCR.

Authors:  David R Kilpatrick; Karen Ching; Jane Iber; Qi Chen; Su-Ju Yang; Lina De; A J Williams; Mark Mandelbaum; Hong Sun; M Steven Oberste; Olen M Kew
Journal:  J Virol Methods       Date:  2013-12-07       Impact factor: 2.014

9.  Virulent variants emerging in mice infected with the apathogenic prototype strain of the parvovirus minute virus of mice exhibit a capsid with low avidity for a primary receptor.

Authors:  Mari-Paz Rubio; Alberto López-Bueno; José M Almendral
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene.

Authors:  Kok Keng Tee; Tommy Tsan-Yuk Lam; Yoke Fun Chan; Jon M Bible; Adeeba Kamarulzaman; C Y William Tong; Yutaka Takebe; Oliver G Pybus
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.